


C53404


BEST AVAILABLE COPY

FIG. 1 NMR SPECTRUM OF 3-HYDROXY-3-MERCAPTO-METHYLQUINUCLIDINE


TMS




SOLVENT;  $\text{CDCl}_3$   
250 MHz- NMR




853404

FIG. 2 250 MHz NMR of AF-102(cis: trans) the HCl salts in  $\text{CDCl}_3$ 


AF-102 (cis:trans)



AF-102 (cis)



AF-102 (trans)




BEST AVAILABLE COPY

853404

BEST AVAILABLE COPY

FIG. 3 250 MHz- NMR OF AF-102A (HCl)



SOLVENT:  $\text{CDCl}_3$





FIG.4 250 MHz- NMR OF AF-102B (HCl) IN  $\text{CDCl}_3$







FIG 5

FIG. 6 IR SPECTRUM OF AF102A


102A 02/11/85 14.39.01



000404

FIG 7. IR SPECTRUM OF AF102B

1028 02/11/83 13.55.24






Fig. 8 Initial latency measures and retention-test latency measures (sec.) of the AF64A and CSF-injected groups, before and after physostigmine or saline administration.



892404

BEST AVAILABLE COPY




Fig. 9: Initial latency measures and retention-test latency measures (sec.) of the AF64A and CSF-injected groups, before and after AF102B or saline administration.

853404

BEST AVAILABLE COPY




Fig. 10 : Retention-test latency measures during 6 trials of extinction.

853404

BEST AVAILABLE COPY




Fig. 11 : Retention-test latency measures during 4 trials of "extinction + latent extinction"




Fig. 12: Retention-test latency measures (sec.) of the AF64A and CSF-injected groups, after second administration of AF102B or saline.




FIG.13 : Retention- test latency measures(sec.) of the AF64A and CSF- injected groups, after AF102B or saline administration.

BEST AVAILABLE COPY

853404




FIG.14: Latency measures (sec.) of the AF64A and CSF- injected groups before and after and saline administration.

[Cross-hatched] CSF-Before Treatment  
 [Vertical lines] AF64A-Before Treatment  
 [White] Soline-Treatment  
 [Diagonal lines] AF102B-Treatment (1 mg/kg p.o.)

AF102B

76a




FIG.15 : Retention- test latency measures(sec.) of the AF64A and CSF- injected groups, after AF1028 or saline administration.




FIG 16 : Escape latency measures, in blocks of 2 trials, of the AF64A and CSF-injected groups, after physostigmine administration.



BEST AVAILABLE COPY




FIG. 17 : Escape latency measures of the AF64A and CSF-injected groups after AF102B administration; MM test.

853404

BEST AVAILABLE COPY




FIG. 18 Average error in the RAM of AF64A- and CSF-injected rats after saline and AF102B administration.




FIG.19 Average error in the RAM of AF64A- and CSF-injected rats after saline and physostigmine administration, respectively.